Its technology combines minimally invasive surgical procedures with biocompatible, bio-enhanced medical devices, creating new treatment opportunities for a range of ophthalmic conditions, including keratoconus and glaucoma.

Keratoconus affects more than 2% of the global population. It typically develops during puberty and progressively worsens into adulthood, affecting men and women at similar rates. To treat this condition, RECORNEA has developed GROSSO® Reshaper, the first nitinol corneal implant designed to help patients restore their vision.

For the treatment of glaucoma – which affects more than 80 million people worldwide and is the leading cause of irreversible blindness – RECORNEA is developing GLAUCOMESH, an implantable microfiltration device designed to provide safer and more stable drainage of intraocular fluid.

Through its pioneering approach, RECORNEA aims to transform the treatment of eye diseases by delivering solutions that improve patients’ quality of life and redefine the standards of clinical practice in ophthalmology.